Date Title Description PDF
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

Date Title Description PDF
04 Oct 2018 Share capital increases and reductions Private placement capital increase addressed to institutional investors, excluding  preferential subscription rights Download
02 Oct 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the third quarter of 2018 Download
24 Sep 2018 Others on business performance and financial information Updated information on business, financial position and risk factors Download
24 Sep 2018 Share capital increases and reductions Intention to raise gross proceeds by means of an offer addressed to institutional investors, excluding preferential subscription rights Download
26 Jul 2018 Información sobre resultados ROVI releases the 2018 first half results presentation Download

Pages